Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H12N2O6S |
Molecular Weight | 288.277 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(COC(N)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
InChI
InChIKey=IKQNRQOUOZJHTR-UWBRJAPDSA-N
InChI=1S/C10H12N2O6S/c1-3(13)5-7(14)12-6(9(15)16)4(19-8(5)12)2-18-10(11)17/h3,5,8,13H,2H2,1H3,(H2,11,17)(H,15,16)/t3-,5+,8-/m1/s1
DescriptionSources: http://adisinsight.springer.com/drugs/800000518Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10508039 and http://www.genome.jp/dbget-bin/www_bget?dr:D09849
Sources: http://adisinsight.springer.com/drugs/800000518
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10508039 and http://www.genome.jp/dbget-bin/www_bget?dr:D09849
Ritipenem (FCE 22101), a penem antibiotic, penicillin binding protein inhibitor, is potent against both gram-positive and -negative bacteria, and its acetoxymethyl ester (FCE 22891; ritipenem-acoxil) is orally available. Ritipenem is manufactured by Tanabe Seiyaku in the ritipenem acoxil prodrug form, which can be taken orally. It is not FDA approved in the United States.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10508039 |
0.076 nM [IC50] | ||
Target ID: map00550 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D09849 |
|||
Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/7473551 |
|||
Target ID: Staphylococcus aureus growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/7473551 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
MEN 10700, a new penem antibiotic: in-vitro activity and its correlation with beta-lactamase stability, PBP affinity and diffusion through the bacterial cell wall. | 1998 May |
|
Potent bacteriolytic activity of ritipenem associated with a characteristic profile of affinities for penicillin-binding proteins of Haemophilus influenzae. | 1999 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8935119
Curator's Comment: Can also be used intravenously https://www.ncbi.nlm.nih.gov/pubmed/2732142
Ritipenem-acoxil was orally administered at 200 mg for 14 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7473551
Ritipenem inhibited Escherichia coli growth with MIC = 1ug/ml
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C260
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10339MIG
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL70088
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
DTXSID60868840
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
65633
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
Ritipenem
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
100000080594
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
D4SL77931L
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
84845-57-8
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
C72840
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
6969
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
C040033
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | |||
|
m9634
Created by
admin on Sat Dec 16 17:50:08 GMT 2023 , Edited by admin on Sat Dec 16 17:50:08 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY